Oncology News

Oncology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kao J et al. - Addition of SU (25 to 37.5 mg) to IGRT is tolerable in patients with oligometastases, without potentiation of RT toxicity. On the basis of promising antitumor responses observed with this novel combination, a multi-institutional phase 2 trial using SU 37.5 mg/RT 50 Gy is ongoing.